Stockreport

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Entrada Therapeutics, Inc.  (TRDA) 
PDF BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of pat [Read more]